To be immunogenic, or not to be: that's the iPSC question.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 23561437.
- Also identified by DOI 10.1016/j.stem.2013.03.008.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The unexpected finding that autologous induced pluripotent stem cell (iPSC)-derived teratomas are immunogenic in syngeneic hosts sparked pessimism over their therapeutic potential; however, two recent reports (Guha et al., 2013 and Araki et al., 2013; the latter in this issue of Cell stem cell) contradict previous findings, showing no immunogenicity of in vitro differentiated syngeneic iPS-derived cells and supporting their safety.